European Psychiatry - Volume 33

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S711

Laboratorios Farmacéuticos Rovi-S.A., R&D, Madrid, Spain

SGS Exprimo NV, Exprimo, Mechelen, Belgium

∗

Corresponding author.

Introduction

Risperidone-ISMis a new long-acting intramuscular

formulation intended to achieve sustained plasma concentrations

over 4weeks without oral supplementation. The clinical efficacy

to risperidone has been associated with 65–80% occupancy of

dopamine D2 receptor (D2RO) and a mean C

max

between 7.5 ng/mL

and 80 ng/mL.

Aim

Use a population PK/PD model to predict the PK and the

D2RO for Risperidone-ISM in schizophrenic patients and to charac-

terize the relationship among doses, in order to guide dose selection

for a future Phase-III trial.

Methods

A population PK/PD analysis for Risperidone-ISM using

Monolix software was conducted based on 6641 plasma samples

from two Phase-I studies (17 healthy subjects and 31 schizophrenic

subjects, respectively) and 1 Phase-II study (60 schizophrenic sub-

jects). Simulations were subsequently undertaken predicting the

steady state PK and D2RO after multiple Risperidone-ISM doses

administered every 28 days for 12weeks.

Results

Doses of 75 and 100mg, administered either in gluteal or

deltoid muscle, were predicted to result in median C

max

and C

trough

that stayed between 7.5 ng/mL and 80 ng/mL. At steady state 75mg

and 100mg dose (gluteal) achieved a D2RO average [min–max]

of 70.8% [61.4–80.4] and 74.3% [66.2–82.1], respectively; a 75-mg

and 100-mg dose (deltoid) achieved a D2RO average [min–max] of

69.3% [56.5–80.3] and 73.0% [61.8–82.1], respectively. The model

estimated that the 65% D2RO occurs within first 8 h after treatment.

Conclusions

Simulations were carried out supporting doses of

75mg and 100mg Risperidone-ISM to show the greatest efficacy

and safety potential to be assessed in the future Phase-III trial.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2118

EV1134

Electroconvulsive treatment in

Parkinson’s disease and psychosis:

A case report

T. Aparicio Reinoso

∗

, S. Gonzalez Parra

Hospital Dr. R Lafora, Psychiatry, Madrid, Spain

∗

Corresponding author.

Background

Drug induced parkinsonism is a common side effect.

Objective

The present report describes the case of a

schizophrenic patient who developed a parkinsonism after receiv-

ing antipsychotic drugs and who had improved his schizophrenia

and parkinsonism after electrovulsive therapy.

Case summary

We report the case of a man, who is 35 years

old and was admitted to a psychiatric ward, due to decompen-

sated schizophreniawith psychotic features. The patient developed

pronounced parkinsonian features, which did not improve with

discontinuation of the drug or with carbidopa/levodopa. After sev-

eral unsuccessful treatments, the patient was treated with ECT and

showed improvement in both diseases.

Results

The patient’s response to this treatment justifies the use

of ECT in patients with both syndromes: a psychosis productive

and Parkinson’s disease. Even the maintenance therapy can estab-

lish the initial response achieved and keep it through time. We

should keep in mind that the management of these patients, can be

extremely difficult because the medications used to both disorders

are antagonistic.

Conclusion

ECT can be considered in patients with a psychiatric

illness associated with parkinsonism.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.